



Final Appraisal Recommendation

Advice No: 2512 – October 2012

Paliperidone palmitate (Xeplion[®]▼) 50 mg, 75 mg, 100 mg and 150 mg prolonged release suspension for injection

Resubmission by Janssen-Cilag Ltd

Recommendation of AWMSG

Paliperidone palmitate (Xeplion[®]▼) prolonged release suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone; and in selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, without prior stabilisation with oral treatment when psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

Additional note:

- AWMSG is of the opinion that paliperidone palmitate (Xeplion[®]▼) prolonged release suspension for injection is appropriate for specialist only prescribing within NHS Wales for the above recommendation.

In reaching the above recommendation AWMSG has taken account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Janssen-Cilag Ltd
Date of first issue	October 2012
Last reviewed	August 2016



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2512:
Paliperidone palmitate (Xeplion[®]▼) 50 mg, 75 mg, 100 mg and 150 mg prolonged release
suspension for injection. October 2012.

